alzheimers

Biogen Stock Price Jump 40% After FDA Approves Alzheimer’s Drug

Biogen Stock Price Jump 40% After FDA Approves Alzheimer’s Drug
8487 | 447

Biogen Inc. (NASDAQ: BIIB) Alzheimer’s drug aducanumab or “Aduhelm” was approved by the Food and Drug Administration (FDA) this morning. Aduhelm is the first drug cleared by the FDA to help fight Alzheimer’s in almost 20 year..

Biogen Rises over 35% on Plans to Pursue FDA Approval

 Biogen Rises over 35% on Plans to Pursue FDA Approval
1919 | 1
 More Buzz

@Newsletter

Sign Up for Weekly Updates

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!

Trending Financialinsiders News

No articles found.

All rights reserved.

No portion of Financialinsiders.com may be duplicated, redistributed or manipulated in any form without our consent, violators will be prosecuted to the full extent of the law. By accessing any information beyond this page, you agree to abide by the Privacy Policy and Terms of Use (Disclaimer).